



BSW Formulary Update – May 2023

New additions to BSWformulary

- [Travoprost PF 40microgram/ml eyedrops in 0.1mL unit dose \(Visutrax®\)](#) – added with **GREEN** TLS as a cost-effective option where PF prostaglandin analogue eyedrop is required. *Note: Local guide for [pharmacological management of glaucoma in primary care](#) under review.*
- [Finerenone tablets 10mg and 20mg](#) – added to formulary in line with [NICE TA877](#) with **AMBER** (initiated) TLS. Finerenone may be prescribed in primary care following specialist initiation and stabilisation. *Note: TLS will be reviewed with a view to being initiated in primary care pending local prescribing guidance.*
- [Maribavir tablets 400mg \(Livtency®\)](#) – added with **RED** TLS in line with NICE TA860 and as per NHSE service specification.

New and Updated Shared Care Agreements/Change in Traffic Light Status

- [Guanfacine tablets \(Intuniv®\) for ADHD in paediatrics](#) – change TLS from RED to **AMBwSCA** in line with updated [BSW SCA for ADHD in children and adolescents](#).
- [Colesevelam 625mg tablets](#) – due to better familiarity in primary care following stock shortages with alternatives, the historic RUH and SFT SCAs have been retired and colesevelam for the treatment of diarrhoea associated with bile salt malabsorption (off label) in patients unable to tolerate colestyramine or where colestyramine is unavailable is assigned a **GREEN** TLS. *Note: colesevelam remains non-formulary for hypercholesterolaemia.*

Prescribing Guidance (includes alignment of guidance for BSW)

- [BSW Guide to Electronic Tools to Support Creatinine Clearance Calculation for DOAC](#) – this standardised local guide aims to achieve consistency across BSW when calculating doses for DOACs. Also see article in MopUp newsletter June 2023 edition [Newsletters - Medicines \(bswtogether.org.uk\)](#)

Minor amendments to Netformulary

- [Malaria prophylaxis and travel health advice](#) – document updated.
- [Adrenaline auto-injectors](#) – updated entry following recent MHRA Emerade® safety alert.

What the BSW CCG formulary team are currently working on

- Reviewing the national NHSE [Shared Care Protocols](#) for implementation locally. The BSW APC has prioritised adoption of these according to existing local protocols (and their date of review) and patient safety factors. As a result, amiodarone and valproate have been selected for implementation.
- Updating BSW Shared Care Agreements for Subcutaneous methotrexate.
- Reviewing the contraceptive chapter of the BSW formulary.



Bath and North East Somerset,
Swindon and Wiltshire Together

- Working with colleagues across RUH/SFT/GWH to update information in our Shared Care Agreement on blood monitoring in females using testosterone as part of HRT regime

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net